HeartSciences

HeartSciences is a privately held medical device company based in Southlake, Texas. Founded in 2007, the company has grown to employ 11 people and has generated $6.4 million in revenue. HeartSciences, formerly known as Heart Test Laboratories, is dedicated to developing accurate and affordable screening tools for the early detection of heart disease. The company's flagship product is the MyoVista wavECG Cardiac Testing Device, a 12-lead resting electrocardiograph that utilizes continuous wavelet transform (CWT) based signal processing. This patented technology focuses on energy-related information rather than conventional voltage-based information, enabling more precise analysis of heart activity. HeartSciences aims to make early heart disease detection more accessible through its innovative technology. HeartSciences has invested over $30 million in research and development, seeking to disrupt the electrocardiography industry which has seen limited technological advancements in recent decades. The company is led by CEO Mark Hilz and Chairman Andrew Simpson, experienced entrepreneurs with backgrounds in technology and finance. For more information about HeartSciences and its products, visit their website at heartsciences.com.